The North America viscosupplementation treatment for arthritis market size is expected to grow at a CAGR of 8.54% during the forecast period (2025–2033). Viscosupplementation offers a less invasive treatment option compared to surgery, making it more attractive to patients seeking alternatives to joint replacement. This preference for non-surgical solutions is fueling market growth.
North America viscosupplementation treatment for arthritis refers to a medical treatment used to manage osteoarthritis, particularly in the knee, hip, and hand joints. This treatment involves the injection of hyaluronic acid (HA) or similar substances directly into the affected joints. Hyaluronic acid is a naturally occurring substance that helps lubricate the joints and acts as a shock absorber. Over time, as the cartilage in the joints wears down due to OA, the viscosity and quality of synovial fluid (which helps in joint lubrication) decreases. Viscosupplementation restores this fluid, reducing friction, relieving pain, and improving joint mobility.
The increasing prevalence of osteoarthritis (OA) is a major driver of the viscosupplementation treatment market in North America. Osteoarthritis, a degenerative joint disease, affects millions of individuals, leading to chronic pain and mobility issues.
This growing patient pool fuels the demand for viscosupplementation as a non-surgical pain relief option. Increasing awareness and early diagnosis further support market expansion, making viscosupplementation a preferred treatment alternative.
The growth of the North America viscosupplementation treatment is restrained by the availability of alternative therapies. Patients and healthcare providers often opt for corticosteroid injections, nonsteroidal anti-inflammatory drugs, and regenerative treatments like platelet-rich plasma (PRP) and stem cell therapy. These alternatives offer varying degrees of pain relief and, in some cases, longer-lasting benefits.
Moreover, total knee replacement surgery remains a definitive solution for severe osteoarthritis. As newer biologic treatments gain popularity, viscosupplementation faces competition, limiting its adoption. The preference for cost-effective or more established therapies challenges market growth despite its advantages in non-surgical OA management.
Rising investments in research and development (R&D) are creating significant opportunities for the North American viscosupplementation treatment market. Companies are focusing on improving the efficacy and longevity of hyaluronic acid injections, with the aim to offer more effective, longer-lasting solutions for osteoarthritis (OA) patients.
Moreover, ongoing R&D into combination therapies, such as combining viscosupplementation with regenerative medicine, is expected to enhance treatment outcomes. These innovations are expected to drive market growth by improving patient satisfaction and expanding treatment options.
| ATTRIBUTES | DETAILS |
|---|---|
| Study Period | 2021-2033 |
| Historical Year | 2021-2024 |
| Forecast Period | 2025-2033 |
| By Applications |
|
| By Product |
|
| By End-User |
|
| Regional Insights |
|
Knee osteoarthritis is the dominant segment in North America viscosupplementation treatment. As one of the most common forms of osteoarthritis, it affects millions of individuals, particularly older adults. The rising prevalence of knee osteoarthritis due to aging populations and sedentary lifestyles drives the demand for effective treatments. Viscosupplementation, using hyaluronic acid injections, helps relieve pain, improve joint function, and delay the need for surgery, making it a preferred treatment for knee osteoarthritis.
The three-injection product is the dominant segment in the North American viscosupplementation treatment market. This treatment regimen typically provides longer-lasting relief compared to single injections, making it a popular choice among patients and healthcare providers. The effectiveness of the three-injection protocol in managing osteoarthritis symptoms, combined with improved patient outcomes and cost-effectiveness, contributes to its strong market demand. As a result, this product type is widely adopted in clinical settings.
Hospitals are the dominant end-user segment in the North American viscosupplementation treatment market. These facilities offer advanced healthcare services and have access to the latest medical technologies, making them the primary providers of viscosupplementation treatments. Hospitals' ability to manage complex cases, provide personalized care, and offer a comprehensive approach to arthritis treatment drives their leading position. Moreover, hospitals often have specialized departments such as orthopedic and pain management units, further boosting the demand for viscosupplementation services.
In North America, the U.S. is the largest market for viscosupplementation treatments due to its advanced healthcare infrastructure, high healthcare expenditure, and large aging population. The rising incidence of osteoarthritis, especially among the baby boomer generation, drives demand for non-surgical interventions like viscosupplementation.
For example, in the U.S., approximately 1 in 2 adults will develop symptomatic knee osteoarthritis by age 85, underscoring the growing need for effective treatments. The American healthcare system’s strong reimbursement policies also encourage the adoption of viscosupplementation therapies, supported by programs like Medicare that cover these treatments for qualifying patients.
Canada, while smaller in market share compared to the U.S., is experiencing a steady rise in viscosupplementation adoption. The country’s aging population and the healthcare system’s emphasis on cost-effective, minimally invasive treatments contribute to this trend. Canadian physicians are increasingly turning to viscosupplementation as an alternative to joint replacement surgeries, particularly for patients who are not yet candidates for surgery.
Likewise, initiatives like the Canadian Arthritis Society’s commitment to improving arthritis care are fostering awareness and driving demand for innovative treatments. Both countries are seeing innovations in viscosupplementation products, with a focus on improving treatment outcomes and extending the effectiveness of injections. The focus on R&D, particularly in the U.S., is pivotal in shaping the future of the market in these regions.
